Applied DNA Sciences (NASDAQ:APDN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Applied DNA Sciences (NASDAQ:APDN) in a research note released on Sunday morning. The brokerage issued a hold rating on the technology company’s stock.

Separately, HC Wainwright decreased their target price on Applied DNA Sciences from $2.00 to $1.50 and set a buy rating for the company in a research note on Friday, February 9th.

Applied DNA Sciences Stock Down 12.1 %

Shares of APDN stock opened at $0.29 on Friday. The stock has a 50-day simple moving average of $0.48 and a 200 day simple moving average of $0.66. Applied DNA Sciences has a fifty-two week low of $0.28 and a fifty-two week high of $1.86. The stock has a market capitalization of $4.92 million, a P/E ratio of -0.54 and a beta of 0.07.

Shares of Applied DNA Sciences are scheduled to reverse split on the morning of Thursday, April 25th. The 1-20 reverse split was announced on Thursday, April 25th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, April 25th.

Applied DNA Sciences (NASDAQ:APDN) last announced its earnings results on Thursday, February 8th. The technology company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.22. Applied DNA Sciences had a negative return on equity of 159.93% and a negative net margin of 80.14%. The business had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $0.70 million. On average, sell-side analysts anticipate that Applied DNA Sciences will post -0.63 earnings per share for the current year.

Hedge Funds Weigh In On Applied DNA Sciences

An institutional investor recently bought a new position in Applied DNA Sciences stock. Silverberg Bernstein Capital Management LLC acquired a new position in Applied DNA Sciences, Inc. (NASDAQ:APDN) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 98,301 shares of the technology company’s stock, valued at approximately $61,000. Silverberg Bernstein Capital Management LLC owned approximately 0.72% of Applied DNA Sciences at the end of the most recent quarter. 22.22% of the stock is currently owned by hedge funds and other institutional investors.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.